Abstract

REPOSITIONING OF PROTON PUMP INHIBITORS AS ANTICANCER AGENTS FOR TARGETING LYMPHOMA AND BREAST CANCER BY MOLECULAR DOCKING STUDIES

Sharanabasav B. Biradar*, Prasad Malagi, B. S. Kittur, Mallikarjun Poleshi, Shwetha Hiremath, Sweta Kattimani, Vaishnavi Bang and Veeramani V.

ABSTRACT

Drug Repositioning/repurposing, as a smart way to exploit new molecular targets of a known drug, has been gaining more Interest in the discovery of PPIs as antitumoral &chemo sensitive agents. PPIs as benzimidazole derivatives, which are essentially H+K +ATPase inhibitors. In recent years, exploiting thenew application of PPIs in anticancer field has become a hot research topic. Therefore, it is of interest to reprofiling drugs against Lymphoma & Breastcancer target using molecular docking analysis. Results showed that known drugs such as Omeprazole, Pantaprazole, Rabeprazole & Lansoprazole has high binding affinity with mobile receptors for consideration as potential inhibitors.

Keywords: PPIs, Drug Repositioning, Molecular Docking.